BCL2L1 and cancer: We indeed reported that treatment of BCL-xL-dependent cancer cell lines with BH3 mimetics targeting BCL-xL, systematically spares individual cells with the highest levels of this protein suggesting BH3 mimetic-resistant residual binding between BCL-xL and proapoptotic proteins [24].